Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.
Cancer Lett. 2020 Jun 28;480:4-14. doi: 10.1016/j.canlet.2020.03.019. Epub 2020 Mar 24.
Osteosarcoma is a common, highly malignant tumor of the musculoskeletal system in young people. Compared with simple amputation in the past, the application of neoadjuvant chemotherapy significantly improved the 5-year survival rate and limb-salvage rate of tumor patients without metastasis. However, the survival rate of patients with metastatic disease treated with neoadjuvant chemotherapy has remained stagnant over the past 30 years despite repeated attempts of adding neoadjuvant chemotherapy agents into the regimen or enhancing the chemotherapy drug dose. In this study, we revealed that macrophages, stimulated by neoadjuvant chemotherapy agents, could reduce the sensitivity of osteosarcoma cells to the drugs. Furthermore, we found that this phenomenon was strongly related to the secretion of the interleukin-1beta by macrophages. Our findings may provide new ideas for improving the efficiency of neoadjuvant chemotherapy for osteosarcoma.
骨肉瘤是一种常见的、高度恶性的青少年骨骼肌肉系统肿瘤。与过去单纯的截肢相比，新辅助化疗的应用显著提高了无转移肿瘤患者的 5 年生存率和保肢率。然而，尽管反复尝试在方案中加入新辅助化疗药物或增加化疗药物剂量，转移性疾病患者的生存率在过去 30 年中仍然停滞不前。在这项研究中，我们揭示了新辅助化疗药物刺激的巨噬细胞可降低骨肉瘤细胞对药物的敏感性。此外，我们发现这种现象与巨噬细胞分泌白细胞介素-1β密切相关。我们的发现可能为提高骨肉瘤新辅助化疗的效率提供新的思路。
